Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023
Share
Easywell Biomedicals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 69.47 million compared to TWD 34.92 million a year ago. Net loss was TWD 24.71 million compared to TWD 37.33 million a year ago. Basic loss per share from continuing operations was TWD 0.22 compared to TWD 0.33 a year ago.
For the six months, sales was TWD 106.44 million compared to TWD 69.99 million a year ago. Net loss was TWD 73.42 million compared to TWD 89.51 million a year ago. Basic loss per share from continuing operations was TWD 0.64 compared to TWD 0.78 a year ago.
Easywell Biomedicals Inc. is a Taiwan-based company principally engaged in the research, development, production and sale of raw materials and temperature measurement products. The raw materials are applied in the manufacture of medicament for the treatment of epilepsy, pain and fever, antihypertensive and diuretic, skeletal muscle relaxants, among others. The Company's diagnostic devices include ear thermometers and digital clinical thermometers. The Company distributes its products mainly in Taiwan, the Americas and Europe.